Who Owns VRAX?

Virax Biolabs Group Limited — Institutional Ownership & 13F Holdings

$0.13

-0.00 (-2.01%)

Market Cap

$868K

Shares Outstanding

4,341,956

Institutional Holders

4

Total Inst. Value

$57K

% of Float Held

QoQ Holder Change

Institutional data as of Q1 2025

New Positions

3

Closed Positions

6

Increased

0

Decreased

1

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1UBS Group AG$26K22,425
2TWO SIGMA SECURITIES, LLCNew$16K13,627
3CITADEL ADVISORS LLCNew$15K13,539
4HRT FINANCIAL LPNew$1513,507

Biggest Buyers & Sellers This Quarter

Top Buyers

FundShares AddedValue
TWO SIGMA SECURITIES, LLCNew+14K$16K
CITADEL ADVISORS LLCNew+14K$15K
HRT FINANCIAL LPNew+14K$15

Top Sellers

FundShares RemovedValue
UBS Group AG-15K$26K

Related Stocks

Frequently Asked Questions

How many institutional investors hold VRAX?

As of Q1 2025, 4 institutional investors report holding VRAX (Virax Biolabs Group Limited) in their 13F filings.

Which hedge fund owns the most VRAX?

The largest institutional holder of VRAX is UBS Group AG with $26K in shares.

Are institutions buying or selling VRAX?

This quarter, 3 institutions opened new positions in VRAX and 6 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.